title: Novel approaches to prevent leukemia relapse following allogeneic hematopoietic cell transplantation.
abstract: Allogeneic hematopoietic cell transplantation is curative for patients with high-risk leukemia, but disease recurrence remains a major cause of treatment failure. New tools are now available to potentially identify patients with minimal residual disease who are at high risk for treatment failure. These improvements in disease detection allow for new opportunities to prevent relapse. The transplant course can be conceptualized into the pretransplant, peritransplant, and posttransplant periods. This article discusses the differing transplant interventions aimed at reducing relapse in each of these periods, focusing on new approaches that are currently being conceived or in early-stage clinical trials.
authors.affiliation: Pediatric Hematology, University of Minnesota Amplatz Children's Hospital, MMC 366, 420 Delaware Street SE, Minneapolis, MN 55455, USA. verneris@umn.edu
authors.forename: Michael R
authors.initials: MR
authors.lastname: Verneris
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Burke
mesh_terms: D036101:Cord Blood Stem Cell Transplantation; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000517:prevention & control / Q000628:therapy*; D015470:Leukemia, Myeloid, Acute / Q000517:prevention & control / Q000628:therapy; D018365:Neoplasm, Residual; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000517:prevention & control / Q000628:therapy; D012008:Recurrence; D014184:Transplantation, Homologous
references.citation: Blood. 2005 May 1;105(9):3449-57
references.pmid: 15657178
references.citation: Blood. 2007 Apr 1;109(7):2791-3
references.pmid: 17119111
references.citation: Pediatr Blood Cancer. 2009 Dec 15;53(7):1289-94
references.pmid: 19731318
references.citation: Blood. 2007 Oct 1;110(7):2761-3
references.pmid: 17579184
references.citation: N Engl J Med. 2004 Nov 25;351(22):2265-75
references.pmid: 15564543
references.citation: Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15113-8
references.pmid: 14657335
references.citation: Br J Haematol. 2010 Apr;149(1):14-21
references.pmid: 20136826
references.citation: Blood. 2009 Aug 13;114(7):1319-30
references.pmid: 19414858
references.citation: Br J Haematol. 2009 Dec;147(5):691-9
references.pmid: 19744131
references.citation: Bone Marrow Transplant. 2007 Jun;39(12):767-73
references.pmid: 17438586
references.citation: Blood. 1995 Jun 1;85(11):3005-20
references.pmid: 7756636
references.citation: J Clin Oncol. 2009 Nov 1;27(31):5175-81
references.pmid: 19805687
references.citation: Blood. 2009 Dec 24;114(27):5444-53
references.pmid: 19786617
references.citation: Biol Blood Marrow Transplant. 2009 Mar;15(3):360-6
references.pmid: 19203727
references.citation: Blood. 2009 Jun 25;113(26):6567-71
references.pmid: 19389879
references.citation: J Clin Invest. 2010 Apr;120(4):1310-23
references.pmid: 20200450
references.citation: Blood. 2006 Jun 15;107(12):4961-7
references.pmid: 16493003
references.citation: Blood. 2007 Mar 1;109(5):2008-13
references.pmid: 17068155
references.citation: Blood. 2007 Feb 1;109(3):1322-30
references.pmid: 17038536
references.citation: Clin Cancer Res. 2008 Dec 15;14(24):8295-301
references.pmid: 19088047
references.citation: Blood. 2009 Oct 29;114(18):3793-802
references.pmid: 19724059
references.citation: Best Pract Res Clin Haematol. 2008 Sep;21(3):455-66
references.pmid: 18790449
references.citation: J Clin Oncol. 1997 Feb;15(2):433-44
references.pmid: 9053463
references.citation: Blood. 2000 Mar 1;95(5):1572-9
references.pmid: 10688810
references.citation: Blood. 2006 Mar 1;107(5):2184-91
references.pmid: 16254140
references.citation: Blood. 2005 Jul 15;106(2):458-63
references.pmid: 15817679
references.citation: Bone Marrow Transplant. 2009 Jan;43(2):107-13
references.pmid: 18776928
references.citation: Clin Cancer Res. 2005 May 15;11(10):3879-88
references.pmid: 15897589
references.citation: Cancer. 2009 May 1;115(9):1899-905
references.pmid: 19235255
references.citation: Br J Haematol. 2009 Sep;146(6):669-74
references.pmid: 19650884
references.citation: Biol Blood Marrow Transplant. 2008 Sep;14(9 Suppl):16-22
references.pmid: 18721776
references.citation: Acta Oncol. 2007;46(2):250-5
references.pmid: 17453378
references.citation: Leukemia. 2005 May;19(5):814-21
references.pmid: 15772700
references.citation: J Clin Oncol. 2010 Feb 20;28(6):955-9
references.pmid: 20085940
references.citation: Blood. 2006 Apr 1;107(7):2643-52
references.pmid: 16352804
references.citation: Blood. 1999 Jun 1;93(11):3662-71
references.pmid: 10339472
references.citation: Blood. 2001 Nov 15;98(10):3174-5
references.pmid: 11721685
references.citation: Med Phys. 2005 Oct;32(10):3214-24
references.pmid: 16279075
references.citation: Blood. 2003 Oct 1;102(7):2379-86
references.pmid: 12791647
references.citation: Blood. 2005 Apr 15;105(8):3051-7
references.pmid: 15632206
references.citation: Clin Cancer Res. 2009 Feb 1;15(3):832-9
references.pmid: 19188153
references.citation: Blood. 2009 Nov 5;114(19):4293-9
references.pmid: 19706886
references.citation: J Clin Oncol. 2009 Jan 20;27(3):377-84
references.pmid: 19064980
references.citation: Lancet. 2007 Jun 9;369(9577):1947-54
references.pmid: 17560447
references.citation: Lancet Oncol. 2009 May;10(5):489-500
references.pmid: 19345145
references.citation: N Engl J Med. 2004 Nov 25;351(22):2276-85
references.pmid: 15564544